Magnesium Bisglycinate 4-Week Trial: Small but Meaningful Insomnia Score Improvement
A 4-week randomized double-blind placebo-controlled trial of magnesium bisglycinate (commonly called magnesium glycinate), one of the most-recommended sleep supplements, was published in Nature and Science of Sleep. The result is small but meaningful.
Trial design
A 4-week, home-based, randomized double-blind placebo-controlled trial in US adults reporting poor self-rated sleep quality.
Intervention: Elemental magnesium 250 mg + glycine 1,523 mg (the magnesium and glycine equivalents of magnesium bisglycinate) once daily for 4 weeks.
Primary endpoint: Change in Insomnia Severity Index (ISI) score. ISI is a 7-item 0-28 scale (≤7 normal, 8-14 mild, 15-21 moderate, 22-28 severe).
Participants: General adults reporting poor sleep quality. Not clinically diagnosed insomnia, but a general population.
Core results
ISI score reduction: Meaningful reduction in the magnesium bisglycinate arm vs placebo. Effect size d=0.2 (small effect size). Statistically significant but clinically moderate.
Timing: Most of the effect emerged within the first 14 days. Maintained through week 4.
Side effects: Magnesium arm reported fewer side effects than placebo (possibly because magnesium itself reduced general somatic complaints).
Exploratory analysis: Greater effect in the subgroup with lower dietary magnesium intake. A “high responder” signal.
How to interpret a small effect size
Effect size d=0.2 is small. How should it be read?
A small effect size shouldn’t be reduced to “no effect.” Even small effect sizes are clinically meaningful when these conditions hold.
Large applicable population: Sleep quality decline is reported by 30-40% of populations. Small effect × large population = meaningful public health impact.
Low side effects: With small side effects, even small effects are reasonable on risk-benefit grounds. Magnesium bisglycinate has well-established safety.
Low cost: Compared to prescription sleep aids (zolpidem, trazodone) or behavioral cognitive therapy, low cost.
High-responder population: Those with low dietary magnesium see larger effects. Use is reasonable after self-assessment.
For severe insomnia (ISI 22-28), it’s insufficient as monotherapy. It’s adjunctive.
Differences across magnesium forms
Commercial magnesium supplements come in different forms with distinct absorption, side effects, and targets.
Bisglycinate (glycinate): Bound to glycine. Good absorption, low GI side effects. Glycine itself supports sleep through neural calming. First choice when sleep is the priority.
Citrate: Good absorption. Stimulates GI motility, also used for constipation. Some people experience diarrhea.
Oxide: Cheapest but lowest absorption. Effective only for constipation.
Malate: Some clinical use for muscle pain and chronic fatigue.
L-threonate: Possibly crosses the blood-brain barrier. Cognitive target.
Chloride: Topical (spray) use. Partial transdermal absorption.
Sulfate (Epsom salt): Bath use. Weak transdermal absorption but relaxing effect.
For sleep, bisglycinate is first choice. Both glycine and magnesium contribute to GABA system and neural calming.
Glycine’s role
Importantly, this trial used bisglycinate (magnesium + glycine), not magnesium alone. Glycine itself has sleep effects.
Glycine 3 g/day trials report shortened sleep latency, improved self-rated sleep quality, and reduced next-day fatigue. This trial’s 1,523 mg glycine is roughly half that, but the synergy with magnesium may compensate.
Pure glycine supplements are also commercially available and can be used with or without magnesium.
Who’s a good fit
Best suited.
Mild sleep quality decline: ISI 8-14 mild insomnia. Self-reported insufficient sleep, difficulty falling asleep, mid-night awakening.
Low dietary magnesium intake: Low vegetable, nut, and bean intake. Processed-food-heavy diets.
Muscle cramps and restless legs: Magnesium can support both.
Stress-related insomnia: GABA system calming for stress-related sleep difficulties.
Pregnancy/breastfeeding: Generally safe but consult a clinician.
Where effects are limited
Severe insomnia (ISI 22-28): Insufficient as monotherapy. Cognitive behavioral therapy (CBT-I) and physician evaluation needed.
Sleep apnea: Cause is breathing disruption, not sleep quantity. Magnesium doesn’t help. Sleep study needed.
Underlying kidney function decline: Magnesium is excreted by kidneys. Risk of accumulation in kidney dysfunction. Confirm normal kidney function.
Dose and side effects
General recommended dose: Elemental magnesium 200-400 mg/day (RDA 420 mg men, 320 mg women).
Clinical doses: 250 mg in this trial. Some trials use up to 400 mg.
GI side effects: Diarrhea and GI discomfort most common, especially with citrate and oxide forms. Less so with bisglycinate.
Caution with kidney dysfunction: Discuss with a clinician for chronic kidney disease.
Drug interactions: Some antibiotics (tetracyclines, quinolones) and bisphosphonates (osteoporosis drugs) have absorption interference. Take 2 hours apart.
Connection to the sleep matrix
Sleep improvement requires more than a single supplement. Matrix approach.
Layer 1: Sleep hygiene. Regular sleep schedule, dark bedroom, caffeine cutoff at 2 PM, alcohol limited, exercise (3+ hours before bed), screens off 1 hour before bed.
Layer 2: Cognitive behavioral therapy (CBT-I). First-line for chronic insomnia. Larger and more lasting effects than drugs.
Layer 3: Supplements. Magnesium bisglycinate 250-400 mg + glycine, or melatonin 0.3-3 mg (start low), L-theanine, valerian, etc.
Layer 4: Prescription drugs. After clinician consultation. Zolpidem, trazodone, ramelteon, etc.
Combined with this quarter’s critical window hypothesis (perimenopausal cognition), GLP-1 era matrix (muscle/face/bone/cognition), and aging mechanism matrix, sleep is one axis of mechanism-by-mechanism differentiation. No single supplement solves everything.